Vol 8, No 2 (2022)
Research paper
Published online: 2022-06-23

open access

Page views 4330
Article views/downloads 337
Get Citation

Connect on Social Media

Connect on Social Media

Analysis of hospital admissions of rheumatoid arthritis patients in the context of everyday clinical practice

Karolina Nowak1, Olga Gumkowska-Sroka2, Przemysław Kotyla1
Rheumatology Forum 2022;8(2):60-68.


Rheumatoid arthritis is a chronic autoimmune connective tissue disease. Among all autoimmune diseases, rheumatoid arthritis is still recognised as having the most complicated pathogenesis. The importance of early diagnosis of RA and the prompt implementation of effective treatment that will lead to remission should be emphasised. The introduction of biological drugs for the treatment of arthritis at the end of the 20th century proved to be a „milestone  in rheumatology. These drugs have been targeted to stop or slow down the progression of the disease. However, not all treated patients will benefit from such treatment since a significant proportion of patients do not respond to the treatment. The study aimed to analyse in real-world clinical practice patients admitted to a typical rheumatological department. Patients were analysed in terms of biological treatment, age, admission procedure, gender, comorbidities, reduction in disability, as well as articular and extra-articular complications. Most of the hospitalised patients were women, married people and people living in the city. Most of the hospitalised patients are 61 to 80 years old. It is worth noting that biologically treated patients — 43 people, were hospitalised more than once a year. Usually, they received biological drugs on a scheduled basis, once a month. Studies show that patients included in the drug programme have fewer mobility limitations and fewer articular and extra-articular complications. They are between the ages of 41 and 60 and have a university degree.

Article available in PDF format

View PDF Download PDF file


  1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003; 423(6937): 356–361.
  2. Mueller AL, Payandeh Z, Mohammadkhani N, et al. Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies. Cells. 2021; 10(11).
  3. Smolen J, Aletaha D, McInnes I. Rheumatoid arthritis. The Lancet. 2016; 388(10055): 2023–2038.
  4. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010; 376(9746): 1094–1108.
  5. Björk M, Dragioti E, Alexandersson H, et al. Inflammatory Arthritis and the Effect of Physical Activity on Quality of Life and Self-Reported Function: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2022; 74(1): 31–43.
  6. Dey M, Parodis I, Nikiphorou E. Fatigue in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Comparison of Mechanisms, Measures and Management. J Clin Med. 2021; 10(16).
  7. Fiehn C. Treatment of rheumatoid arthritis and spondylarthritis with biologics. Der Internist. 2022; 63(2): 135–42.
  8. Smolen JS, Breedveld FC, Burmester GR, et al. T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010; 69(4): 631–637.
  9. Miossec P. Rheumatoid arthritis: still a chronic disease. Lancet. 2013; 381(9870): 884–886.
  10. Nerurkar L, Siebert S, McInnes IB, et al. Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry. 2019; 6(2): 164–173.
  11. Ostor AJ, Sawant R, Qi CZ, et al. Value of Remission in Patients with Rheumatoid Arthritis: A Targeted Review. Adv Ther. 2022; 39(1): 75–93.
  12. Chan SJ, Yeo HY, Stamp LK, et al. What Are the Preferences of Patients With Rheumatoid Arthritis for Treatment Modification? A Scoping Review. Patient. 2021; 14(5): 505–532.
  13. Kumar P, Alok R, Das S, et al. Distribution of rheumatological diseases in rural and urban areas: An adapted COPCORD Stage I Phase III survey of Lucknow district in north India. International Journal of Rheumatic Diseases. 2018; 21(11): 1894–1899.
  14. Hsiao B, Fraenkel L. Patient preferences for rheumatoid arthritis treatment. Curr Opin Rheumatol. 2019; 31(3): 256–263.
  15. Nash P. 2019 update: EULAR RA management recommendations, efficacy and safety systematic literature reviews. Ann Rheum Dis. 2020; 79(6): 679–680.
  16. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79(6): 685–699.
  17. Crowson CS, Gunderson TM, Dykhoff HJ, et al. Comprehensive assessment of multimorbidity burden in a population-based cohort of patients with rheumatoid arthritis. RMD Open. 2022; 8(1).
  18. Ahmed S, Jacob B, Carsons SE, et al. Treatment of Cardiovascular Disease in Rheumatoid Arthritis: A Complex Challenge with Increased Atherosclerotic Risk. Pharmaceuticals (Basel). 2021; 15(1).
  19. Park E, Griffin J, Bathon JM. Myocardial Dysfunction and Heart Failure in Rheumatoid Arthritis. Arthritis Rheumatol. 2022; 74(2): 184–199.
  20. Restivo V, Candiloro S, Daidone M, et al. Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus. Autoimmun Rev. 2022; 21(1): 102925.
  21. Rezuș E, Macovei LA, Burlui AM, et al. Ischemic Heart Disease and Rheumatoid Arthritis-Two Conditions, the Same Background. Life (Basel). 2021; 11(10).